Every Form 4 that Fulcrum Therapeutics, Inc. (FULC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow FULC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FULC filings page.
Kevin Tang and affiliated Tang Capital entities, as 10% owners of Fulcrum Therapeutics, reported indirect open-market purchases totaling 167,616 shares of common stock on July 16–17, 2026. Reported weighted-average prices were $3.56 and $3.52 per share, with trade ranges from $3.46 to $3.60. These shares are held through Tang Capital funds, and the trades were not reported under a Rule 10b5-1 trading plan.
Investment entities associated with Kevin Tang and Tang Capital Management LLC, each a ten percent owner of Fulcrum Therapeutics, Inc., reported open-market purchases of 249,946 shares of common stock from July 13–15, 2026 at prices ranging from $3.50 to $3.60 per share. Reported prices are weighted averages for multiple trades within these ranges.
Following these transactions, the reporting group’s indirect beneficial ownership increased to 6,913,329 shares, held across Tang Capital Partners, LP, Tang Capital Partners International, LP, Tang Capital Partners III, Inc., and Tang Capital Partners IV, Inc., in which Kevin Tang has a pecuniary interest.
Fulcrum Therapeutics director Sonja Banks received a new stock option grant. The award covers 32,000 shares of common stock at an exercise price of $3.66 per share and expires on June 29, 2036. All shares are scheduled to vest on the first anniversary of the June 30, 2026 grant date, or earlier immediately before the first annual stockholder meeting after the grant date, subject to continued service.
Fulcrum Therapeutics director Katina Dorton received a new stock option award covering 32,000 shares of Common Stock. The option carries an exercise price of $3.66 per share and expires on June 29, 2036. It was granted at no upfront cost and is scheduled to vest in full on the first anniversary of the June 30, 2026 grant date or earlier, immediately before the first annual stockholder meeting after the grant date, subject to continued service. Following this grant, Dorton holds 32,000 stock options directly from this award.
Fulcrum Therapeutics director Robert J. Gould received a stock option grant for 32,000 shares of common stock. The option has an exercise price of $3.66 per share and expires on June 29, 2036. It was granted as compensation, not through an open-market transaction.
According to the terms, all 32,000 shares are scheduled to vest on the first anniversary of the June 30, 2026 grant date or, if earlier, immediately before the first annual meeting of stockholders after that date, as long as Gould continues to serve the company. Following this grant, his reported option holdings from this filing total 32,000 shares.
Fulcrum Therapeutics director Kate Haviland received a new stock option grant. She was awarded options covering 32,000 shares of Fulcrum Therapeutics common stock at an exercise price of $3.6600 per share.
The option was granted as of June 30, 2026 and is scheduled to vest in full on the first anniversary of the grant date or, if earlier, immediately before the first annual meeting of stockholders after the grant date, assuming continued service. Following this grant, she holds options for 32,000 shares directly.
Fulcrum Therapeutics director Rachel K. King received a grant of stock options covering 32,000 shares of common stock. These options give her the right to buy shares at an exercise price of $3.66 per share, aligning part of her compensation with the company’s future performance.
The option grant is scheduled to vest in full on the first anniversary of the June 30, 2026 grant date, or earlier immediately before the first annual stockholder meeting after that date, as long as she continues in service. After this grant, she holds options for 32,000 underlying shares that expire on June 29, 2036. This is a compensation-related award rather than an open-market purchase or sale.
Fulcrum Therapeutics, Inc. director James A. Geraghty received a grant of stock options covering 32,000 shares of common stock. The options have an exercise price of $3.66 per share and expire on June 29, 2036. According to the grant terms, all 32,000 options are scheduled to vest on the first anniversary of the June 30, 2026 grant date, or earlier immediately before the first annual stockholder meeting after that date, subject to his continued service.
Fulcrum Therapeutics director Colin Hill received a stock option grant covering 32,000 shares of Common Stock. The option has an exercise price of $3.66 per share and was granted as a compensation award, not as an open-market purchase or sale.
The option was granted on June 30, 2026 and is scheduled to vest in full on the first anniversary of the grant date or, if earlier, immediately before the first annual meeting of stockholders after the grant date, subject to continued service. Following this grant, Hill holds options for 32,000 shares directly, with an expiration date of June 29, 2036.
Fulcrum Therapeutics, Inc. director Alan Ezekowitz received a stock option grant covering 32,000 shares of common stock. The option has an exercise price of $3.66 per share and expires on June 29, 2036.
According to the terms, the option is scheduled to vest in full on the first anniversary of the June 30, 2026 grant date or, if earlier, immediately before the first annual stockholder meeting after the grant date, as long as service continues. Following this grant, his reported derivative holdings for this option total 32,000 shares.
Fulcrum Therapeutics director Alan Ezekowitz reported an open-market sale of common stock. He sold 18,000 shares of Fulcrum Therapeutics, Inc. at a weighted average price of $3.6452 per share, executed as multiple trades within a disclosed price range.
The transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person on March 27, 2026. Following this sale, Ezekowitz directly holds 10,927 shares of Fulcrum Therapeutics common stock.
Fulcrum Therapeutics, Inc. director Joshua Lehrer-Graiwer received a grant of stock options covering 64,000 shares of common stock. The options have an exercise price of $8.08 per share and are scheduled to vest in equal monthly installments until April 23, 2029, subject to continued service.
Fulcrum Therapeutics, Inc. director Robert J. Gould sold 15,000 shares of common stock on January 2, 2026 under a Rule 10b5-1 trading plan adopted on August 1, 2025. The weighted average sale price was $10.8726, with individual trades between $10.60 and $11.33.
After these transactions, Gould beneficially owned 469,864 shares of Fulcrum Therapeutics common stock. This amended report updates the previously reported weighted average sale price from $11.8726 to $10.8726.
Fulcrum Therapeutics reported an equity award to its Chief Financial Officer, Alan Musso. On February 2, 2026, he received a stock option to purchase 170,000 shares of common stock at an exercise price of $10.72 per share. Following this grant, he beneficially owns 170,000 derivative securities tied to company stock.
The option is scheduled to vest in equal quarterly installments over four years, beginning on January 1, 2026, and each vesting date requires his continued service. This type of award aligns the CFO’s potential compensation with future stock performance over a multi‑year period.
Fulcrum Therapeutics’ Chief Legal Officer receives new stock option grant. On February 2, 2026, Curtis Gale Oltmans was granted options to purchase 170,000 shares of Fulcrum Therapeutics common stock at an exercise price of $10.72 per share, expiring February 1, 2036.
The options are scheduled to vest in equal quarterly installments over four years, beginning on a vesting commencement date of January 1, 2026, and require his continued service with the company on each vesting date.
Fulcrum Therapeutics director Robert J. Gould reported an automatic stock sale under a pre-set trading plan. On 02/02/2026, he sold 15,000 shares of Fulcrum Therapeutics common stock at a weighted average price of $10.7238 per share, coded as an open market sale.
The transaction was executed pursuant to a Rule 10b5-1 trading plan that he adopted on August 1, 2025, which allows pre-arranged trades. After this sale, Gould beneficially owned 454,864 shares of Fulcrum Therapeutics common stock in direct ownership.
Fulcrum Therapeutics, Inc. reported a stock option grant to its Principal Accounting Officer, Greg Tourangeau. On February 2, 2026, he received a stock option (right to buy) covering 57,000 shares of common stock at an exercise price of $10.72 per share.
The option is scheduled to vest in equal quarterly installments over four years, beginning on the vesting commencement date of January 1, 2026, contingent on his continued service on each vesting date. Following this grant, he beneficially owns 57,000 derivative securities directly.
Fulcrum Therapeutics, Inc. reported a new equity award to its President and Chief Executive Officer, Alex Sapir. On February 2, 2026, Sapir received a stock option to buy 650,000 shares of Fulcrum common stock at an exercise price of $10.72 per share.
The option is scheduled to vest in equal quarterly installments over four years, beginning on the vesting commencement date of January 1, 2026, and depends on Sapir’s continued service on each vesting date. Following this grant, Sapir beneficially owns 650,000 derivative securities directly.
Fulcrum Therapeutics director Robert J. Gould reported a planned sale of company stock. On January 2, 2026, he sold 15,000 shares of Fulcrum Therapeutics common stock at a weighted average price of $11.8726 per share, with individual trade prices ranging from $10.60 to $11.33. These transactions were carried out under a Rule 10b5-1 trading plan that he adopted on August 1, 2025. After this sale, he beneficially owned 469,864 shares of Fulcrum Therapeutics common stock, held directly.
Fulcrum Therapeutics, Inc. Chief Legal Officer Curt Oltmans reported a small stock sale under a pre-arranged trading plan. On 12/15/2025, he sold 3,452 shares of Fulcrum Therapeutics common stock at a price of $12.92 per share, as shown in Table I of the filing.
The filing notes that these sales were made under a Rule 10b5-1 trading plan adopted on August 8, 2025, which is designed to follow preset instructions. After this transaction, Oltmans beneficially owned 10,252 shares, including shares previously acquired through the company’s employee stock purchase plan.
Fulcrum Therapeutics director reports sale of common stock under trading plan. A reporting person serving as a director of Fulcrum Therapeutics, Inc. (FULC) sold 15,000 shares of common stock on 11/19/2025 in an open market transaction at a weighted average price of $11.033 per share. After this sale, the individual beneficially owns 484,864 shares of Fulcrum common stock in direct form. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan that was adopted on August 1, 2025, which is intended to allow systematic selling according to preset instructions.